Antibody-based therapy for solid tumors

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Monoclonal antibodies represent a significant advancement in cancer therapy, offering targeted action distinct from traditional small molecule drugs.
• Their unique pharmacokinetic properties and ability to modulate the immune system are key differentiators in oncology treatment.

Purpose of the Study:

• To review four key monoclonal antibodies used in treating solid tumors: trastuzumab, bevacizumab, cetuximab, and panitumumab.
• To detail their mechanisms of action, clinical trial data for approved and emerging indications, and relevant clinical considerations.

Main Methods:

• Review of literature focusing on approved monoclonal antibodies for solid tumors.
• Analysis of their mechanisms, clinical efficacy, safety profiles, and future development perspectives.

Main Results:

• The reviewed antibodies (trastuzumab, bevacizumab, cetuximab, panitumumab) exert anticancer effects by blocking growth factor signaling and/or down-regulating oncogenic proteins.
• Some antibodies also leverage immune effector mechanisms like antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity.
• Clinical data for approved indications and emerging uses, alongside side effects and dosing, are presented for each antibody.

Conclusions:

• Monoclonal antibodies are effective oncology therapeutics with diverse mechanisms, including direct tumor targeting and immune system activation.
• Understanding their specific actions, clinical data, and potential side effects is crucial for effective patient management.
• Future directions involve antibody engineering, clinical development strategies, and pharmacogenomics to optimize their use in cancer treatment.